BACKGROUND: The dynamics of chlamydia clearance after treatment administration for chlamydial urogenital infection are unknown. We estimated the time to clearance of Chlamydia trachomatis (CT) ribosomal RNA (rRNA) after administration of azithromycin for cervical chlamydial infection using APTIMA Combo 2 (Gen-Probe, Inc., San Diego, CA, USA). METHODS: A total of 115 women diagnosed with urogenital chlamydial infection, defined as a positive APTIMA urine or endocervical specimen, were enrolled in the present study. Vaginal swabs on the day of treatment (Day 0) and on Days 3, 7, 10 and 14 after treatment with 1 g of azithromycin were self-obtained by participants. Specimens were tested in a single laboratory. Our analysis was limited to women who were CT-confirmed by vaginal swab at baseline, who returned all follow-up swabs, and who reported sexual abstinence during the follow-up period (n = 61). RESULTS: Among 61 participants, 48 (79%) had a negative APTIMA at Day 14. Subjects with a negative APTIMA at each time-point were as follows: 0/61 (0%) on Day 0, 7/61 (12%) on Day 3, 28/61 (46%) on Day 7, 40/61 (66%) on Day 10, and 48/61 (79%) on Day 14. Multiple linear regression analysis predicted time to clearance at 17 days (95% confidence interval, 16-18 days) after administration of azithromycin. Seventeen of the 94 participants (18.1%) who screened positive for chlamydia had a negative vaginal swab on Day 0, indicating possible spontaneous clearance of CT. CONCLUSIONS: After treatment, CT rRNA declined with time. As rRNA was still detectable in 21% of the women 14 days after treatment, APTIMA should not be used as a test-of-cure in the 14-day period following azithromycin administration.
BACKGROUND: The dynamics of chlamydia clearance after treatment administration for chlamydial urogenital infection are unknown. We estimated the time to clearance of Chlamydia trachomatis (CT) ribosomal RNA (rRNA) after administration of azithromycin for cervical chlamydial infection using APTIMA Combo 2 (Gen-Probe, Inc., San Diego, CA, USA). METHODS: A total of 115 women diagnosed with urogenital chlamydial infection, defined as a positive APTIMA urine or endocervical specimen, were enrolled in the present study. Vaginal swabs on the day of treatment (Day 0) and on Days 3, 7, 10 and 14 after treatment with 1 g of azithromycin were self-obtained by participants. Specimens were tested in a single laboratory. Our analysis was limited to women who were CT-confirmed by vaginal swab at baseline, who returned all follow-up swabs, and who reported sexual abstinence during the follow-up period (n = 61). RESULTS: Among 61 participants, 48 (79%) had a negative APTIMA at Day 14. Subjects with a negative APTIMA at each time-point were as follows: 0/61 (0%) on Day 0, 7/61 (12%) on Day 3, 28/61 (46%) on Day 7, 40/61 (66%) on Day 10, and 48/61 (79%) on Day 14. Multiple linear regression analysis predicted time to clearance at 17 days (95% confidence interval, 16-18 days) after administration of azithromycin. Seventeen of the 94 participants (18.1%) who screened positive for chlamydia had a negative vaginal swab on Day 0, indicating possible spontaneous clearance of CT. CONCLUSIONS: After treatment, CT rRNA declined with time. As rRNA was still detectable in 21% of the women 14 days after treatment, APTIMA should not be used as a test-of-cure in the 14-day period following azithromycin administration.
Authors: Patricia J Kissinger; Scott White; Lisa E Manhart; Jane Schwebke; Stephanie N Taylor; Leandro Mena; Christine M Khosropour; Larissa Wilcox; Norine Schmidt; David H Martin Journal: Sex Transm Dis Date: 2016-10 Impact factor: 2.830
Authors: Arlene C Seña; Shelly Lensing; Anne Rompalo; Stephanie N Taylor; David H Martin; Laureen M Lopez; Jeannette Y Lee; Jane R Schwebke Journal: J Infect Dis Date: 2012-05-21 Impact factor: 5.226
Authors: Laura C Chambers; James P Hughes; Sara N Glick; Jennifer L Morgan; M Sylvan Lowens; Tashina S Robinson; Sarah S Romano; Gina L Leipertz; Jørgen S Jensen; Christine M Khosropour; David N Fredricks; Matthew R Golden; Lisa E Manhart Journal: Sex Transm Dis Date: 2019-10 Impact factor: 2.830
Authors: William M Geisler; Apurva Uniyal; Jeannette Y Lee; Shelly Y Lensing; Shacondra Johnson; Raymond C W Perry; Carmel M Kadrnka; Peter R Kerndt Journal: N Engl J Med Date: 2015-12-24 Impact factor: 91.245
Authors: Gweneth B Lazenby; Jeffrey E Korte; Sarah Tillman; Florence K Brown; David E Soper Journal: Int J STD AIDS Date: 2016-11-18 Impact factor: 1.359
Authors: Jannie J van der Helm; Leslie O A Sabajo; Antoon W Grunberg; Servaas A Morré; Arjen G C L Speksnijder; Henry J C de Vries Journal: PLoS One Date: 2012-02-29 Impact factor: 3.240